The pituitary cancer market consists of therapies such as surgery, radiation therapy, hormone therapy and chemotherapy used for the treatment of pituitary tumors. Pituitary tumors occur in the pituitary gland which acts as a master endocrine gland that produces hormones that regulate other hormone-secreting glands and organs. Pituitary cancer may arise from adenomas which can grow large enough to compress or invade nearby structures. The need for efficient treatment of pituitary cancer is rising owing to the increasing prevalence of pituitary tumors worldwide which is attributed to various lifestyle and environmental factors.
The Global pituitary cancer market is estimated to be valued at US$ 457.31 Mn in 2024 and is expected to exhibit a CAGR of 9.6% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the pituitary cancer market are Novartis International AG, Pfizer Inc., Ipsen Biopharmaceuticals, Inc., Endocyte, RECORDATI GROUP, Camurus AB, Endeavor Biomedicines, Inc., and Debiopharm International SA. These key players are actively focusing on developing innovative therapies and drug delivery methods for pituitary cancer treatment. For instance, in 2019, Camurus AB received orphan drug designation from the US FDA for CAM2038, a long-acting octreotide formulation, for the treatment of acromegaly and neuroendocrine tumors.
The Pituitary Cancer Market Demand expansion such as increased usage of minimally invasive surgical procedures and development of new targeted therapies. There is a growing demand for novel therapeutic drugs with increased efficacy and reduced side effects. Pharmaceutical companies are investing more in R&D to develop next-generation drugs for pituitary cancer treatment.
Moreover, rising global burden of endocrine disorders, technological advancements in cancer diagnosis, and increasing healthcare expenditure are also contributing to the expansion of the pituitary cancer market across various geographies. Key players are actively focusing on geographic expansions in high growth regions including Asia Pacific and Latin America for further penetrating the market.
Market drivers:
Increasing prevalence of pituitary adenomas globally due to various environmental and lifestyle risk factors is a major market driver. According to the European Society of Endocrinology, non-functioning pituitary adenomas have a prevalence rate of 16.7% in the general population. Rising awareness about early diagnosis and available treatment options is also driving the growth of the pituitary cancer market.
Market restraints:
High cost associated with pituitary cancer targeted therapies poses a major challenge to market growth. Additionally, lack of awareness about pituitary tumors in developing regions and difficulties in pituitary cancer diagnosis initially also restrain the market expansion. Limitations and challenges associated with surgery also acts as a market restraint.
Segment Analysis
The Pituitary Cancer Market Size And Trends is dominated by the non-functioning pituitary adenoma segment. This segment accounts for over 50% of pituitary cancer cases as these tumors do not secrete any hormones. Non-functioning pituitary adenomas are more common compared to hormone-secreting adenomas. The hormone-secreting pituitary adenoma sub-segment is further divided into prolactin-secreting adenomas, growth hormone-secreting adenomas, adrenocorticotropic hormone-secreting adenomas, and thyroid-stimulating hormone-secreting adenomas. Of these, prolactin-secreting adenomas are the most prevalent, followed by growth hormone-secreting adenomas.
Global Analysis
The North America region currently dominates the pituitary cancer market with the highest market share owing to high healthcare expenditure and developed healthcare infrastructure in countries like the US and Canada. The Asia Pacific region is expected to witness the highest growth during the forecast period owing to improving healthcare facilities, rising disposable income, and increasing awareness about cancer diagnosis and treatment in emerging economies of China and India. In addition, increasing collaborations between regional and global market players for expanding operations in Asia would further boost the growth of the pituitary cancer market in the region.
Get More Insights On, Pituitary Cancer Market
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
0 comment